Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
Author:
Funder
None
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)
Link
https://link.springer.com/content/pdf/10.1007/s40263-023-01023-6.pdf
Reference18 articles.
1. Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643–53. https://doi.org/10.1007/s40263-021-00825-w.
2. Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–66. https://doi.org/10.1016/j.clinthera.2020.05.021.
3. Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. CNS Drugs. 2022;36(8):897–915. https://doi.org/10.1007/s40263-022-00938-w.
4. Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300. https://doi.org/10.2147/jep.s256586.
5. ACNP 61st Annual meeting: Poster abstracts P271-P540. Neuropsychopharmacol. 2022;47(S1):220-370. https://doi.org/10.1038/s41386-022-01485-0.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder;Expert Review of Neurotherapeutics;2024-06-25
2. Settling a distracted globe: An overview of psychosocial and psychotherapeutic treatment of attention-deficit/hyperactivity disorder;European Neuropsychopharmacology;2024-06
3. Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants;Expert Opinion on Pharmacotherapy;2024-05-02
4. Adis Summary of Research: Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder;Drugs & Therapy Perspectives;2024-04
5. Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents;Expert Review of Neurotherapeutics;2024-03-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3